Glutamate and Parkinson's disease

Molecular Neurobiology

Volumn 12, Issue 1, 1996, Pages 73-94

  Blandini, Fabio ^a   Porter, Richard H P ^b   Greenamyre, J Timothy ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal ganglia; Bioenergetics; Excitatory amino acids; Excitotoxicity; N methyl D aspartate

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; CALCIUM CHANNEL; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTOXIN;

ANIMAL; BASAL GANGLION; BIOLOGICAL MODEL; BRAIN; ENERGY METABOLISM; HUMAN; METABOLISM; NERVE CELL; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION;

ANIMALS; BASAL GANGLIA; BRAIN; CALCIUM CHANNELS; ENERGY METABOLISM; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; MODELS, NEUROLOGICAL; NEURONS; NEUROTOXINS; NEUROTRANSMITTER AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION;

EID: 0030080245     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02740748     Document Type: Article

References (165)

1. Greenamyre J. T. (1986) The role of glutamate in neurotransmission and in neurologic disease. Arch. Neurol. 43, 1058-1063.
2. Greenamyre J. T. and Porter R. H. P. (1994) Anatomy and physiology of glutamate in the CNS. Neurology 44(Suppl. 8), S7-S13.
3. Fonnum F. (1984) Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 42, 1-11.
4. Kanai Y., Smith C. P., and Hediger M. A. (1993) The elusive transporters with a high affinity for glutamate. Trends Neurosci. 16, 359-370.
5. Watkins J. C. and Evans R. H. (1981) Excitatory amino acid transmitters. Ann. Rev. Pharmacol. Toxicol. 21, 165-204.
6. Nakanishi S. (1992) Molecular diversity of glutamate receptors and implications for brain function. Science 258, 597-603.
7. McBain C. J. and Mayer M. L. (1994) N-methyl-D-aspartic acid receptor structure and function. Physiol. Rev. 74, 723-760.
8. Johnson J. W. and Ascher P. (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325, 529-531.
9. Kleckner N. and Dingledine R. (1988) Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241, 835-837.
10. Williams K., Romano C., Dichter M. A., and Molinoff P. B. (1991) Modulation of the NMDA receptor by polyamines. Life Sci. 48, 469-498.
11. 2+ antagonize NMDA and GABA responses of hippocampal neurons. Nature 328, 640-643.
12. Christine C. W. and Choi D. W. (1990) Effect of zinc on NMDA receptor-mediated channel currents in cortical neurons. J. Neurosci. 10, 108-116.
13. Traynelis S. F. and Cull-Candy S. G. (1990) Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature 345, 347-350.
14. +. Proc. Natl. Acad. Sci. USA 87, 6445-6449.
15. Nowak L., Bregestovski P., and Ascher P. (1984) Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307, 462-465.
16. Sugihara H., Moriyoshi K., Ishii T., Masu M., and Nakanishi S. (1992) Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicing. Biochem. Biophys. Res. Commun. 185, 826-832.
17. Moriyoshi K., Masu M., Isnii T., Shigemoto R., Mizuno N., and Nakanishi S. (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354, 31-37.
18. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnahev N., Sakmann B., and Seeberg P. H. (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256, 1217-1221.
19. Kutsuwada T., Kashiwabuchi N., Mori H., Sakimura K., Kushiya E., Araki K., Meguro H., Masaki H., Kumanishi T., Arakawa M., and Mishina M. (1992) Molecular diversity of the NMDA receptor channel. Nature 358, 36-41.
20. Meguro H., Mori H., Araki K., Kushiya E., Kutsuwada T., Yamazaki M., Kumanishi T., Arakawa M., Sakimura K., and Mishina M. (1992) Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 357, 70-74.
21. Lodge D. and Johnson K. M. (1990) Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol. Sci. 11, 126-133.
22. Rogawski M. A. (1993) Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14, 325-331.
23. Porter R. H. P. and Greenamyre J. T. (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochemistry 64, 614-623.
24. Brorson J. R., Bleakman D., Chard P. S., and Miller R. J. (1992) Calcium directly permeates kainate/alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in cultured cerebellar Purkinje neurons. Mol. Pharmacol. 41, 603-608.
25. Burnashev N., Khodorva A., Jonas P., Helm P. J., Wisden W., Monyer H., Seeberg P., and Sakmann B. (1992) Calcium-permeable AMPA-kainate receptors in fusiform cerebellar glial cells. Science 256, 1566-1570.
26. Hollmann M., O'Shea-Greenfield A., Rodgers S. W., and Heinemann S. J. (1989) Cloning by functional expression of a member of the glutamate receptor family. Nature 342, 643-648.
27. Keinanen K., Wisden W., Sommer B., Werner P., Herb A., Verdoon A., Sakmann B., and Seeberg P. A. (1990) A family of AMPA-selective glutamate receptors. Science 249, 556-560.
28. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 252, 851-853.
29. Sommer B., Keinanen K., Verdoon T. A., Wisden W., Burnashev N., Herb A., Kohler M., Takagi T., Sakmann B., and Seeberg P. H. (1990) Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 249, 1580-1585.
30. Sheardown M. J., Nielson E. O., Hansen A. J., Jacobsen P., and Honoré T. (1990) 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 247, 571-574.
31. Donevan S. D. and Rogawski M. A. (1993) GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/ kainate receptor responses. Neuron 10, 51-59.
32. Olney J. W., Ho O. L., and Rhee V. (1971) Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse central nervous system. Exp. Brain Res. 14, 61-76.
33. Meldrum B. and Garthwaite J. (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11, 379-387.
34. Orrenius S. and Nicotera P. (1994) The calcium ion and cell death. J. Neural Trans. 43 (S1), 1-11.
35. Phelps P. C., Smith M. W., and Trump B. F. (1989) Cytosolic ionized calcium and bleb formation after acute cell injury of cultured rabbit renal tubule cells. Lab. Invest. 60, 630-642.
36. 2+-dependent mechanisms. Arch. Biochem. Biophys. 270, 478-488.
37. Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders Science 262, 689-695.
38. Lazarewicz J. W., Wroblewski J. T., and Costa E. (1990) N-methyl-D-aspartate-sensitive glutamate receptors induce calcium-mediated arachidonic acid release in primary cultures of cerebellar granule cells. J. Neurochem. 55, 1875-1881.
39. Dawson V. L., Dawson T. M., London G. D., Bredt D. S., and Snyder S. H. (1991) Nitric acid mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA 88, 6368-6371.
40. Beckman J. S., Beckman T. W., Chen J., Marshall A., and Freeman A. (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87, 1620-1624.
41. Olney J. W., Sharpe L. G., and Feigin R. D. (1971) Glutamate-induced brain damage in infant primates. J. Neuropath. Exp. Neurol. 31, 464-488.
42. Reynolds I. J. and Hastings T. G. (1995) Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J. Neurosci. 15, 3318-3327.
43. 2+ exchange buffer glutamate-induced calcium loads in cultured cortical neurons. J. Neurosci. 15, 1318-1328.
44. Peng T.-I., Sheu S.-S., and Greenamyre J. T. (1995) Visualization of NMDA-induced mitochondrial calcium uptake in striatal neurons using confocal microscopy. Soc. Neurosci. Abstr. 21, 1343.
45. Kure S., Tominaga T., Yoshimoto T., Tada K., and Narisawa K. (1991) Glutamate triggers internucleosomal DNA cleavage in neuronal cells. Biochem. Biophys. Res. Commun. 179, 39-45.
46. Sonsalla P. K., Nicklas W. J., and Heikkila R. E. (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243, 398-400.
47. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349, 414-418.
48. Benveniste H., Drejer J., Schousboe A., and Diemer N. H. (1984) Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43, 1369-1374.
49. Rothman S. M. and Olney J. W. (1986) Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19, 105-111.
50. Glynn I. M. and Karlish S. J. D. (1975) The sodium pump. Ann. Rev. Physiol. 37, 13-55.
51. +, and adenosine triphosphate in isolated brain synaptosomes. J. Gen. Physiol. 95, 591-616.
52. Novelli A., Reilly J. A., Lysko P. G., and Henneberry R. C. (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451, 205-212.
53. Albin R. L. and Greenamyre J. T. (1992) Alternative excitotoxic hypotheses. Neurology 42, 733-738.
54. Beal M. F., Hyman B. T., and Koroshetz W. (1993) Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 16, 125-131.
55. Novelli A., Reilly J. A., Lysko P. G., and Henneberry R. C. (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451, 205-212.
56. Henneberry R. C. (1989) The role of neuronal energy in neurotoxicity of excitatory amino acids. Neurobiol. Aging 10, 611-613.
57. Zeevalk G. D. and Nicklas W. J. (1990) Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. J. Pharmacol. Exp. Ther. 253, 1285-1292.
58. Beal M. F., Swartz K. J., Hyman B. T., Storey E., Finn S. F., and Koroshetz W. (1991) Amino-oxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. J. Neurochem. 57, 1068-1073.
59. Beal M. F., Brouillet E., Jenkins B., Henshaw R., Rosen B., and Hyman B. T. (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61, 1147-1150.
60. Greene J. G., Porter R. H. P., Eller R. V., and Greenamyre J. T. (1993) Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J. Neurochem. 61, 1151-1154.
61. Greene J. G. and Greenamyre J. T. (1995) Exacerbation of NMDA, AMPA, and L-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate. J. Neurochem. 64, 2332-2338.
62. Beal M. F. (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31, 119-130.
63. Langston J. W., Ballard P. A., Tetrud J. W., and Irwin I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979,980.
64. Kopin I. J. and Markey S. P. (1988) MPTP toxicity: implications for research in Parkinson's disease. Ann. Rev. Neurosci. 11, 81-96.
65. DeLong M. R. (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285.
66. Chiba K., Trevor A., Castagnoli N. Jr. (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120, 574-578.
67. Heikkila R. E., Manzino L., Cabbat F. S., and Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
68. Langston J. W., Irwin I., Langston E. B., and Forno L. S. (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225, 1480-1482.
69. Salach J. I., Singer T. P., Castagnoli N. Jr., and Trevor A. (1984) Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem. Biophys. Res. Commun. 125, 831-835.
70. Javitch J. A., D'Amato R. J., Strittmatter S. M., and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82, 2173-2177.
71. Ramsay R. R., Dadgar J., Trevor A., and Singer T. P. (1986) Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 39, 581-588.
72. Nicklas W. J., Vyas I., and Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2508.
73. +) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem. 56, 1184-1190.
74. Greenamyre J. T., Higgins D. S., and Eller R. V. (1992) Quantitative autoradiography of dihydrorotenone binding to complex I of the electron transport chain. J. Neurochem. 59, 746-749.
75. +) with the rotenone binding site of complex I of the electron transport chain. Soc. Neurosci. Abstr. 19, 407.
76. Cesura A. M., Ritter A., Picotti G. B., and Da Prada M. (1987) Uptake, release, and subcellular localization of 1-methyl-4-phenylpyridinium in blood platelets. J. Neurochem. 49, 138-145.
77. Buckman T. D., Chang R., Sutphin M. S., and Eiduson S. (1988) Interaction of 1-methyl-4-phenylpyridinium ion with human platelets. Biochem. Biophys. Res. Commun. 151, 897-904.
78. Da Prada M., Cesura A. M., Launay J. M., and Richards J. G. (1988) Platelets as a model for neurones? Experientia 44, 115-126.
79. 3H]dihydrorotenone binding to complex I in intact human platelets. Anal. Biochem. 230, 16-19.
80. Hartley A., Stone J. M., Heron C., Cooper J. M. and Schapira A. H. (1994) Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J. Neurochem. 63, 1987-1990.
81. Hatefi Y. (1985) The mitochondrial electron transport and oxidative phosphorylation system. Ann. Rev. Biochem. 54, 1015-1069.
82. Chomyn A., Cleeter M. W. J., Ragan C. I., Riley M., Doolittle R. F., and Attardi G. (1986) URF6, last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit. Science 234, 614-618.
83. Singer T. P. and Ramsay R. R. (1994) The reaction sites of rotenone and ubiquinone with mitochondrial NADH dehydrogenase. Biochim. Biophys. Acta 1187, 198-202.
84. Mizuno Y., Suzuki K., and Ohta S. (1990) Postmortem changes in mitochondrial respiratory enzymes in the brain and a preliminary observation in Parkinson's disease. J. Neurol. Sci. 96, 49-57.
85. Schapira A. H. V., Cooper J. M., Dexter D., Clark J. B., Jenner P., and Marsden C. D. (1990) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
86. Janetzky B., Hauck S., Youdim M. B. H., Riederer P., Jellinger K., Pantucek F., Zöchling R., Boissl K. W., and Reichmann H. (1994) Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett. 169, 126-128.
87. Mizuno Y., Ikebe S., Hattori N., Kondo T., Tanaka M., and Ozawa T. (1993) Mitochondrial energy crisis in Parkinson's disease, in Advances in Neurology (Narabayashi H., Nagatsu T., Yanagisawa N., and Mizuno Y., eds.), Raven, New York, pp. 282-287.
88. Mecocci P., MacGarvey U., Kaufman A. E., Koontz D., Shoffner J. M., Wallace D. C., and Beal M. F. (1993) Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 34, 609-616.
89. Allen K. L., Almeida A., Bates T. E., and Clark J. B. (1995) Changes of respiratory chain activity in mitochondrial and synaptosomal fractions isolated from the gerbil brain after graded ischaemia. J. Neurochem. 64, 2222-2229.
90. Cleeter M. W., Cooper J. M., and Schapira A. H. (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58, 786-789.
91. Jenner P. (1994) Oxidative damage in neurodegenerative disease. Lancet 344, 796-798.
92. Chiueh C. C., Miyake H., and Peng M. (1993) Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism, in Advances in Neurology (Narabayashi H., Nagatsu T., Yanagisawa N., and Mizuno Y., eds.), Raven, New York, pp. 251-258.
93. Youdim M. B. H., Ben-Shachar D., Eshel G., Finberg J. P., and Riederer P. (1993) The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease, in Advances in Neurology (Narabayashi H., Nagatsu T., Yanagisawa N., and Mizuno Y., eds.), Raven, New York, pp. 259-266.
94. Ben-Shachar D., Eshel G., Finberg J. P. M., and Youdim M. B. H. (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441-1444.
95. Dexter D. Y., Wells F. R., Agid F. R., Agid Y., Lees A. J., Jenner P., and Marsden C. D. (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet 2, 1219,1220.
96. Sofic E., Paulus W., Jellinger K., Riederer P., and Youdim M. B. H. (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56, 978-982.
97. Dexter D. T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., Lees A. J., Wells F. R., Jenner P., and Marsden C. D. (1990) Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 5, 16-20.
98. Riederer P., Sofic E., Rausch E. D., Schmidt B., Reynolds G. P., Ellinger K., and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
99. Jellinger K. A., Kienzl E., Rumpelmaier G., Paulus W., Riederer P., Stachelberger H., Youdim M. B. H., and Ben-Sacher D. (1993) The level of iron and ferritin in substantia nigra in Parkinson's disease, in Advances in Neurology (Narabayashi H., Nagatsu T., Yanagisawa N., and Mizuno Y., eds.), Raven, New York, pp. 267-272.
100. Dexter D. T., Carayon A., Javoy-Agid F., Agid Y., Wells F. R., Daniel S. E., Lees A. J., Jenner P., and Marsden C. D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
101. Dexter D. T., Jenner P., Schapira A. H. V., and Marsden C. D. (1992) Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann. Neurol. 32, S94-S100.
102. Dedman D. J., Treffry A., Candy J. M., Taylor G. A. A., Morris C. M., Bloxham C. A., Perry R. H., Edwardson J. A., and Harrison P. M. (1992) Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. Biochem. J. 287, 509-514.
103. Fridovich I. (1989) Superoxide dismutases. An adaptation to a paramagnetic gas. J. Biol. Chem. 264, 7761-7764.
104. Nakazono K., Watanabe N., Matsuno K., Sasaki J., Sato T., and Inous M. (1991) Does superoxide underlie the pathogenesis of hypertension? Proc. Natl. Acad. Sci. USA 88, 10,045-10,048.
105. Perry T. L., Godin D. V., and Hansen S. (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310.
106. Perry T. L. and Yong V. W. (1986) Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67, 269-274.
107. Sofic E., Lange K. W., Jellinger K., and Riederer P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130.
108. Saggu H., Cooksey J., Dexter D., Wells F. R., Lees A., Jenner P., and Marsden C. D. (1989) A selective increase in the particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53, 692-697.
109. Marttila R. J., Lorentz H., and Rinne U. K. (1988) Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86, 321-331.
110. Mithöfer K., Sandy M. S., Smith M. T., and DiMonte D. (1992) Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Arch. Biochem. Biophys. 295, 132-136.
111. Albin R. L., Young A. B., and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
112. McGeorge A. J. and Faull R. L. M. (1989) The organization of the projection from the cerebral cortex to the striatum in the rat. Neurosdence 29, 503-537.
113. Young A. B., Bromberg M. B., and Penney J. B. (1981) Decreased glutamate uptake in subcortical areas deafferented by sensorimotor cortical ablation in the cat. J. Neurosci. 1, 241-249.
114. Moore R. Y., Bhatnagar R. K., and Heller A. (1971) Anatomical and chemical studies of a nigro-neostriatal projection in the cat. Brain Res. 30, 119-135.
115. Gerfen C. R. (1992) The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15, 133-139.
116. Greenamyre J. T. (1993) Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. Neural Trans. 91, 255-269.
117. Strange P. G. (1993) Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov. Disord. 8, 263-270.
118. Anderson J. I., Chase T. N., and Engber T. M. (1992) Differential effect of subthalamic nucleus ablation on dopamine D1 and D2 agonist-induced rotation in 6-hydroxydopamine-lesioned rats. Brain Res. 588, 307-310.
119. Kita H. and Kitai S. T. (1987) Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J. Comp. Neurol. 260, 435-452.
120. Parent A. and Smith Y. (1987) Organization of efferent projections of the subthalamic nucleus in the squirrel monkey as revealed by retrograde labeling methods. Brain Res. 436, 296-310.
121. Robledo P. and Feger J. (1990) Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data. Brain Res. 518, 47-54.
122. Smith Y. and Parent A. (1988) Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res. 453, 353-356.
123. Aides L. D. (1988) Thalamic connectivity of rat somatic motor cortex. Brain Res. Bull. 20, 338-348.
124. 14C-deoxyglucose method in conscious rats. J. Comp. Neurol. 231, 137-149.
125. Sommer B., Keinanen K., Verdoorn T. A., Wisden W., Burnashev N., Herb A., Kohler M., Takagi T., Sakmann B., and Seeburg P. H. (1990) Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 249, 1580-1585.
126. Moriyoshi K., Masu M., Ishi T., Shigemoto R., Mizuno N., and Nakanishi S. (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354, 31-37.
127. Albin R. L., Makowiec R. L., Hollingsworth Z., Dure L. S., Penney J. B., and Young A. B. (1992) Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 46, 35-48.
128. 3H]MK-801 binding in rat brain. J. Neurochem. 60, 1344-1353.
129. Tallaksen-Greene S. J., Wiley R. G., and Albin R. L. (1992) Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Brain Res. 594, 165-170.
130. Landwehrmeyer G. B., Standaert D. G., Testa C. M., Penney J. B., and Young A. B. (1995) NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J. Neurosci. 15, 5297-5307.
131. Tallaksen-Greene S. J. and Albin R. L. (1994) Localization of AMPA-selective excitatory amino acid receptor subunits in identified populations of striatal neurons. Neuroscience 61, 509-519.
132. Yamamoto B. K. and Cooperman M. A. (1994) Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14, 4159-4166.
133. Calabresi P., Mercuri N. B., Sancessario G., and Bernardi G. (1993) Electrophysiology of dopamine-denervated striatal neurons. Brain 116, 433-452.
134. Anderson J. J., Kuo S., and Chase T. N. (1994) Endogenous excitatory amino acids tonically stimulate striatal acetylcholine release through NMDA but not AMPA receptors. Neurosci. Lett. 176, 264-268.
135. Albin R. L., Aldrich J. W., Young A. B., and Gilman S. (1989) Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity. Brain Res. 491, 185-188.
136. 14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents. Exp. Neurol. 113, 171-181.
137. Robledo P. and Feger J. (1990) Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data. Brain Res. 518, 47-54.
138. Tzagournissakis M., Dermon C. R., and Savaki H. E. (1994) Functional metabolic mapping of the rat brain during unilateral electrical stimulation of the subthalamic nucleus. J. Cereb. Blood Flow Metab. 14, 132-144.
139. Blandini F. and Greenamyre J. T. (1995) Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia. Brain Res. 669, 59-66.
140. Blandini F., Porter R. H. P., and Greenamyre J. T. (1995) Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion. Neurosci. Lett. 186, 99-102.
141. Soltis R. P., Anderson L. A., Walters J. R., and Kelland M. D. (1994) A role for non-NMDA excitatory amino acid receptors in regulating the basal activity of rat globus pallidus neurons and their activation by the subthalamic nucleus. Brain Res. 666, 21-30.
142. Porter R. H., Greene J. G., Higgins D. S., and Greenamyre J. T. (1994) Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J. Neurosci. 14, 7192-7199.
143. Klockgether T. and Turski L. (1993) Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann. Neurol. 34, 585-593.
144. Miller W. C. and DeLong M. R. (1987) Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism, in The Basal Ganglia II (Carpenter M. B. and Jayrman A., eds.), Plenum, New York, pp. 415-427.
145. Mitchell I. J., Clarke C. E., Boyce S., Robertson R. G., Peggs D. E., Sambrook M. A., and Crossman A. R. (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32, 213-226.
146. Aziz T. Z., Peggs D., Sambrook M. A., and Crossman A. R. (1991) Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov. Disord. 6, 288-292.
147. Benazzouz A., Gross C. H., Feger J., Boraud T., and Bioulac B. (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosci. 5, 382-389.
148. Bergman H., Wichmann T., and DeLong M. R. (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249, 1436-1438.
149. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349, 414-418.
150. Sonsalla P. K., Nicklas W. J., and Heikkila R. E. (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243, 398-400.
151. Greene J. G. and Greenamyre J. T. (1995) Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J. Neurochem. 64, 430-436.
152. Uitti R. J., Rajput A. H., Ahlskog J. E., Offord K. P., Ho M. M., Prasad M., Rajput A., and Basran P. (1993) Amantadine treatment is an independent predictor of improved survival in parkinsonism. Canad. J. Neurol. Sci. 20, 235.
153. Limousin P., Pollak P., Benazzouz A., Hoffman D., Le Bas J. F., Broussolle E., Perret J. E., and Benabid A. L. (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345, 91-95.
154. Brotchie J. M., Mitchell I. J., Sambrook M. A., and Crossman A. R. (1991) Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord. 6, 133-138.
155. Klockgether T., Turski L., Honoré T., Zhang Z., Gash D. M., Kurlan R., and Greenamyre J. T. (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30, 717-723.
156. Klockgether T. and Turski L. (1990) NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann. Neurol. 28, 539-546.
157. Carlsson M. and Carlsson A. (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Trans. 75, 221-226.
158. Schmidt W. J. and Bubser M. (1989) Anti-cataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Phamacol. Biochem. Behav. 32, 621-623.
159. Löschmann P. A., Lange K. A., Kunow M., Rettig K.-J., Jähnig P., Honoré T., Turski L., Wachtel H., Jenner P., and Marsden C. D. (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. J. Neural Trans. [PD-Sect.] 3, 203-213.
160. Greenamyre J. T., Eller R. V., Zhang Z., Ovadia A., Kurlan R., and Gash D. M. (1994) Anti-parkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35, 655-661.
161. Kornhuber J., Bormann J., Hubers M., Rusche K., and Riederer P. (1991) Effects of the L-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol. 206, 297-300.
162. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166, 589, 590.
163. Klockgether T., Jacobsen P., Löschmann P. A., and Turski L. (1993) The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J. Neural Trans. 5, 101-106.
164. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P., and Marsden C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
165. Dexter D. T., Holley A. E., Flitter W. D., Slater T. F., Wells F. R., Daniel S. E., Lees A. J., Jenner P., and Marsden C. D. (1994) Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9, 92-97.